Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of monoclonal CD 5 þ B lymphocytes. 1, 2 These clonal B cells are largely noncycling, and their accumulation is secondary to decreased apoptosis/cell death rather than increased proliferation. 3 Previously, we have shown that CLL B cells spontaneously secrete vascular endothelial growth factor (VEGF). 4 VEGF is a member of the platelet-derived growth factor superfamily and an endothelial cell-specific growth factor. It stimulates vasodilatation and cell proliferation, increases permeability and migration, and promotes endothelial cell survival. [5] [6] [7] [8] VEGF plays a vital role as a regulator of bloodvessel growth and development 6, [9] [10] [11] [12] [13] [14] [15] [16] [17] and exerts its effects by interacting with two high-affinity receptors, VEGF-R1 (Flt-1) and VEGF-R2 (KDR/Flk). VEGF-R1 18, 19 and VEGF-R2 20, 21 are tyrosine kinase receptors that transphosphorylate and also phosphorylate specific tyrosine residues of SH2 domain containing signaling molecules. 22, 23 VEGF-R1 undergoes weak liganddependent tyrosine phosphorylation, whereas VEGF-R2 has a much stronger phosphorylation response. Such differences in signal transduction properties of these receptors likely lead to diverse functions of VEGF. 19, 22 Thus, VEGF-R1 has been shown to mediate cell migration and differentiation, whereas VEGF-R2 has been shown to regulate cell proliferation and survival. 11, 12, 19, 24, 25 In addition to secretion of VEGF, we have previously shown that CLL B cells also express constitutively activated VEGF-R1 and VEGF-R2. 26 Recently, we have shown that the addition of exogenous VEGF to CLL B cells can increase their apoptotic resistance through upregulation of XIAP and Mcl-1 expression. 26 Based on these observations, we have postulated CLL B cells may use the VEGF autocrine pathway for cell survivorship. 26 While these observations are intriguing, studies exploring the effects of neutralization of VEGF secreted by CLL B cells are required to confirm an autocrine VEGF pathway. In addition, the signaling molecule(s) that is responsible for transducing cellular signals from the VEGF receptor to the nucleus in CLL B cells has yet to be identified. It has been postulated that the major signaling pathway downstream of the VEGF-VEGF receptor interaction is the serine/threonine kinase mitogen-activated protein kinase. 27 However, involvement of signal transducers and activators of transcription (STAT) proteins in the VEGF signaling pathway have also been reported. 28 STAT proteins are activated in response to a number of cytokines, growth factors, and hormones. [29] [30] [31] Receptor-bound STAT proteins initially become tyrosine-phosphorylated either by receptor intrinsic or associated tyrosine kinase activities. 32 The activation of the STAT proteins is usually featured by phosphorylation of tyrosine sites followed by phosphorylation at specific serine sites. After the binding of a specific ligand to its receptor, STAT proteins are activated, dimerize, translocate to the nucleus, and bind to specific target gene promoters to initiate transcription. To date, seven mammalian STATs (STAT 1, 2, 3, 4, 5A/B, and 6) have been identified. The tyrosine-phosphorylated STATs can dimerize (either as homodimers or in some cases as heterodimers, as seen with Stat1/2, Stat1/3, and Stat5a/5b) via reciprocal phosphotyrosine-SH2 domain interaction. 30 For both STAT 1 and STAT 3, the phosphorylation of Ser-727 enhances DNAbinding affinity 33 and activation of transcription. 34 Recently, several reports demonstrated that phosphorylated (serine site 727) STAT 1 and STAT 3 are overexpressed in CLL B cells, [35] [36] [37] although the biologic importance of increased activated STAT proteins in CLL B-cell signaling and survivorship is unknown.
To further investigate a potential autocrine VEGF survival pathway and more closely examine the role of STAT molecules in CLL B cells, we studied the effect of VEGF neutralization and the dynamics of STAT 1 and 3 molecules following VEGF-VEGF-R interaction in CLL B cells. In this study, we show that: (i) CLL B cells express constitutive serine-phosphorylated (p)-STAT-1 and -3; (ii) these activated STATs physically complex with VEGF receptors 1 and 2; (iii) VEGF induces STAT 3 activation and nuclear translocation of STAT 3, (iv) inhibition of VEGF receptor activation with tyrosine kinase inhibitors (EGCG and SU 11657) specifically decreases serine p-STAT-3; and (v) VEGF neutralizing antibodies (bevaczumab and an antibody designated as mab 293) inhibit serine phosphorylation of STAT 3 and induce apoptosis in CLL B cells. These observations substantiate the presence of a VEGF-based autocrine pathway in CLL B cells, suggest that STAT 3 plays a role in VEGF receptor signaling, and demonstrate that inhibition of the VEGF receptor pathway leads to apoptosis in CLL B cells.
Materials and methods

Patient selection and purification of lymphocytes
Blood was obtained from healthy donors or CLL patients who had provided written informed consent. The laboratory study was approved by the Mayo Clinic Institutional Review Board according to the regulations of the Declaration of Helsinki. All CLL patients had a confirmed diagnosis using the NCI working group definition. 38 Patients in this cohort were from all Rai stages and had not been treated for at least 6 weeks prior to blood processing for this study. Peripheral blood mononuclear cells (PBMC) were separated from heparinized venous blood by density gradient centrifugation. To remove adherent cells, PBMC were suspended in RPMI 1640 supplemented with 10% fetal calf serum (FCS) and incubated in plastic dishes at 371C for 1 h prior to collection of nonadherent cells. To obtain at least 95% purity of CLL B cells, nonadherent cells were depleted of T cells by incubation with sheep erythrocytes. For some experiments, we purified CLL B cells from magnetic bead columns. In brief, highly purified CD19 þ B cells (495%) were obtained from PBMC by standard negative selection using a cocktail of subset-specific antibodies conjugated with magnetic beads (Miltenyi Biotech, Auburn, CA, USA). These purified CLL B cells were then either used immediately for the laboratory studies described below or cryopreserved in RPMI 1640, 20% FCS, and 10% DMSO and stored in liquid nitrogen until use.
Reagents
Immunological reagents that recognize the following antigens were purchased from the indicated suppliers: STAT 
Cell culture
Primary CLL B cells and human splenic B cells were sorted by CD 19 þ (Miltenyi Biotec, Auburn, CA, USA) and were then cultured in serum-free AIM-V (Gibco BRL, USA) and RPMI (Biomol, USA) supplemented with 10% FCS, respectively. Cells were maintained at 371C in an atmosphere containing 95% air-5% CO 2 (v/v).
Immunoblotting analysis
Primary CLL B cells were cultured in six-well tissue culture dishes and treated with either vehicle or drug for 24 h. The treated cells were then washed three times with calcium, magnesium-free Dulbecco's phosphate-buffered saline (PBS) and solubilized in alkylation buffer (6 M guanidine hydrochloride, 250 mM Tris-HCl, pH 7.4 at 211C, and 10 mM EDTA supplemented immediately before use with 150 mM 2-mecaptoethanol and 1 mM phenylmethylsulfonyl fluoride). Samples were then dialyzed into 4 M urea and then 0.1% SDS. Protein extracts were then separated on 5-15% SDS-PAGE acrylamide gels and transferred to nitrocellulose and blocked with 10% Trissaline milk (TSM). Primary antibodies were diluted in the 10% TSM milk and incubated overnight on the shaker at room temperature. After extensive washing with 1 Â PBS containing 0.05% Tween 20 for 3 Â 15 min, the blot was then incubated with horseradish peroxidase-conjugated secondary antibody (KPL Inc., Gaitherburg, MD, USA) diluted 1:8000 in 10% TSM for 1 h at room temperature. After extensive washing with 1 Â PBS containing 0.05% Tween 20 for another 30 min, bound antibodies were detected by ECL chemiluminescence (Amersham Pharmacia, Piscataway, NJ, USA).
Immunoprecipitation
Freshly isolated primary leukemic CLL B cells were treated with either vehicle or drug for 24 h. Total protein extracts from primary leukemic cells were obtained by lysing cells in cold lysis buffer (30 mM Tris-HCL, pH 7.4, 150 mM NaCl, 1% glycerol, 1% Triton X-100, and 2 mM EDTA) in the presence of phosphatase inhibitors (100 mM NaF, 10 mM Na 4 P 2 O 4 , 1 mM Na 2 VO 4 ,) and protease inhibitors (10 mg/ml leupeptin, 10 mg/ml pepstatin A, and 1 mM PMSF). After centrifugation to remove all cell debris, protein extracts were immunoprecipitated overnight at 41C on high-speed rotator with either anti-FLT1 (6.12R1) or anti-KDR (3.83R2). The beads were washed with lysis buffer 3 times prior to resuspension into loading buffer and subjected to SDS-PAGE-acrylamide gel electrophoresis (5-15%) under reducing conditions. Proteins were subsequently transferred to nitrocellulose membrane. Blots were then blocked with 10% TSM milk and followed by incubation with primary, phosphotyrosine 4G10, and secondary antibodies. Secondary antimouse Ig-G-HRP for both VEGF-R1 (FLT1) and VEGF-R2 (KDR) was used at 1:8000. The ECL chemiluminescence detection system and ECL film (Amersham Pharmacia, Piscataway, NJ, USA) were used to visualize the presence of proteins on the cellulose blots.
Nuclear extraction assay
Isolated CLL B cells were cultured with or without VEGF 165 (100 ng/ml) for 30 min at 371C. Nuclear lysates were prepared using NE-PER Nuclear and Cytoplasmic Extraction Kit from Pierce (Rockford, IL, USA). Nuclear extract was then immunoprecipitated with either p-STAT-1 (Ser 727) or p-STAT-3 (Ser 727) antibodies.
Immunostaining analysis
Freshly isolated primary CLL B cells were cultured in serum-free AIM-V medium (Life Technologies, Rockville, MD, USA) for 24 h. These cells were then stimulated with or without VEGF 165 (100 ng/ml) for 20 min. After the stimulation, these cells were later washed twice with 1 Â PBS prior to slide preparation. The slides were then fixed with 3.7% formaldehyde for 15 min at the room temperature on the shaker and washed twice with 1 Â PBS. The cells on the slides were extracted with 0.1% Triton-X for 5 min at room temperature. After the extraction, the slides were washed twice with 1 Â PBS prior to blocking with 5% BSA on 1 Â PBS for 30 min. Slides were incubated with the primary antibodies of interest for 1 h, washed twice with 1 Â PBS and later subjected to the appropriate fluorescein isothiocyanate (FITC) secondary antibody for an additional 30 min. After the incubation, the slides were washed twice with 1 Â PBS. The slides were finally stained with either propidium iodide (red nucleus) or DAPI (blue nucleus) for nuclear staining and subjected to Leica and Leica QFISH (Germany) software for capturing the images.
Confocal microscopy
Freshly isolated CLL B cells were cultured in serum-free AIM-V media. After 24-h culture, cells were replenished with fresh serum-free media. To visualize VEGF receptor-STAT colocalization, all cells were treated with VEGF 165 (100 ng/ml) for 45 min at 41C to recruit ligand-bound receptor at the cell surface, and warmed to 371C for the time indicated, to enable endocytosis. Cells were fixed in 3.7% formaldehyde for 15 min at room temperature on the shaker. The slides were washed twice with 1 Â PBS. The cells on the slides were extracted with 1% Triton-X for 5 min at room temperature. After the extraction, the slides were washed twice with 1 Â PBS prior to blocking with 5% BSA on 1 Â PBS for 30 min. After a wash in PBS, cells were incubated with mouse monoclonal anti-STAT 3(Ser 727) with either rabbit polyclonal anti-Flt (VEGF-R1) (Santa Cruz Biotechnology, Flt C-17, sc-316) or rabbit polyclonal anti-Flk (VEGF-R2) (Flk C1158, sc-504). The slides were then extensively washed with PBS and incubated with secondary antibodies (Vector, FITC-conjugate anti-mouse and rabbit, respectively). Images were collected using the LSM 510 program on a Zeiss confocal microscope.
Apoptosis/cell death assay
Primary CLL B cells (1 Â 10 6 cells) were treated with either vehicle or specific drug for 24 h. After the treatment, cells were rinsed with 1 Â PBS and analyzed for apoptosis/cell death levels by means of an FITC-labeled annexin-V/propidium iodide assay. These cells were directly analyzed in a FACScan (Becton Dickinson, Sunnyvale, CA, USA) with a sample size of 10 000 cells gated on the basis of forward and side scatter. Storing and processing of data was accomplished using FACScan software as described previously.
Results
CLL B cells express constitutive serine p-STAT-1 and p-STAT-3
Others have reported that CLL B cells express serine p-STAT-1 and p-STAT-3. 37 We first sought to reproduce these observations initially using immunofluorescence to assay for the presence of serine p-STAT-1 and p-STAT-3 in CLL B cells ( Figure 1 and Table 1 ).
Although there was evidence for serine p-STAT-1 and p-STAT-3 in CLL B cells, tyrosine p-STAT-1 and p-STAT-3 were not detected (Table 1) Serine p-STAT-1 and p-STAT-3 complex with both VEGF-R1 and VEGF-R2 on CLL B cells While several signaling pathways can be induced following VEGF-VEGF-R interaction, 17 preliminary experiments using specific inhibitors of these pathways (JAK, MAPK, PI3 K, SRC) did not block p-STAT-3 activation or induce apoptosis in CLL B cells (data not shown). A number of previous studies have found that receptor-STAT coupling required cytokine stimulation. [39] [40] [41] [42] [43] Since we previously reported that CLL B cells spontaneously secrete high levels of VEGF 4 and that CLL B cell exposure to VEGF increases the level of VEGF receptor phosphorylation, 26 we wondered if CLL B cells exhibit VEGF-R-STAT molecule interaction and activation. We performed B cell immunoprecipitation assays to evaluate the VEGF-R-STAT molecule interaction in CLL B cells. Serine p-STAT-1 and p-STAT-3 were found to be physically associated with both VEGF-R1 and VEGF-R2 in CLL B cells (Figure 3) . Immunoprecipitation of serine p-STAT-3/1 resulted in the co-immunoprecipitation of VEGF-R1 and VEGF-R2 (Figure 3a and b) . When these blots were stripped and reprobed for tyrosine phosphorylation, we did indeed find tyrosine-phosphorylated protein at the expected molecular weight of VEGF receptor strongly suggesting that activated VEGF receptors were physically complexed with the serine p-STAT proteins. Similarly, if we initially immunoprecipitated for VEGF-R1 or VEGF-R2, p-STAT-3 and p-STAT-1were coimmunoprecipitated, and when that blot was stripped and reprobed for tyrosine sites again tyrosine-phosphorylated protein of the expected molecular weight of VEGF-R was also found (data not shown). In contrast, similar experiments where we blotted for the nonphosphorylated STAT 3 suggest only the phosphorylated STAT 3 complexes with VEGF receptors (data not shown).
VEGF 165 selectively induces activation and nuclear translocation of STAT 3 but not STAT 1 in primary CLL B cells To further verify the nuclear translocation of STATs, we performed nuclear extraction assays to determine which STAT molecules were present in the nucleus after VEGF stimulation. Figure 4c shows that incubation with VEGF resulted in nuclear translocation of serine p-STAT-3 but no increase in nuclear serine p-STAT-1. Collectively, these data suggest that VEGF induces selective activation and nuclear translocation of serine p-STAT-3 but not STAT-1 in primary CLL B cells.
Since VEGF serves as a ligand for both VEGF-R1 and VEGF-R2, we performed similar experiments using exogenous placental-derived growth factor (PLGF), which selectively activates VEGF-R1, to dissect the role of the -R1 and -R2 receptor in p-STAT-3 (serine 727) translocation. PLGF did not Table 1 Immunofluorescence Immunoprecipitation analysis confirms that CLL B cells express serine p-STAT-1 and p-STAT-3. Freshly isolated normal splenic B cells and CLL B cells were subjected to lysis buffer. Protein extract (500 mg) was prepared and then subjected to immunoprecipitation with p-STAT antibodies of interest. Cell lysate was then subjected to SDS-PAGE (7.5%) and transferred to nitrocellulose. Blots were then reprobed with the p-STAT antibodies for p-STAT-1 or p-STAT-3, respectively. A549 whole-cell lysate is from a non-small carcinoma cell line used as a positive control for p-STAT-1 (Ser 727) and p-STAT-3 (Ser 727), and SKNMC whole-cell lysate is used as a positive control for p-STAT-1 (Tyr 701). Note: Slp B ¼ CD 19
þ splenic B cells; P ¼ patient. Serine p-STAT-1 and p-STAT-3 complex with activated VEGF-R1 and VEGF-R2 receptor on CLL B cells. Freshly isolated primary CLL B cells and splenic normal B cells were subjected to lysis buffer. Protein extract (500 mg) was prepared and immunoprecipitated by serine p-STAT-1 and p-STAT-3 antibody and then transferred to nitrocellulose. Blots were then probed first with specific p-STAT-1 or p-STAT-3. This blot strategy showed the expected molecular weight (MW) of 92 kDa. Then the blot was stripped and probed for either VEGF-R1 or VEGF-R2 antibody to show total VEGF-R protein and was found to show protein at the expected MW of 230 kDa. Finally, this blot was stripped and reprobed for phosphorylated protein using an antibody specific for tyrosine (4G10, Upstate, NY, USA). This last immunoblot was found to detect a tyrosinephosphorylated protein on the 230 kDa protein.
to the nucleus by receptor-mediated endocytosis. 39, 44, 45 To examine the role of VEGF receptors in STAT 3 translocation, confocal microscopy experiments using antibodies specific for both p-STAT-3 and VEGF receptors (VEGF-R1 and VEGF-R2) were performed to detect the localization of VEGF receptor and STAT molecules in CLL B cells. CLL B cells were incubated for 45 min at 41C in the presence of VEGF (time 0) followed by warming to 371C. 45 At time 0, STAT 3 and VEGF receptors R1 (Figure 5a ) and R2 ( Figure 5c ) were primarily located in the cytoplasm and cell surface membrane. Following VEGF stimulation after 30 min at 371C, STAT 3, VEGF-R1 (Figure 5b) , and VEGF-R2 (Figure 5d ) were located at the perinuclear zone. These findings demonstrate that stimulation with VEGF induces STAT 3 and VEGF-R1 and VEGF-2 to localize to the same cellular compartment (perinuclear membrane) raising the possibility of receptor-mediated endocytosis.
Tyrosine kinase inhibitors block VEGF receptor phosphorylation, selectively inhibit the level of p-STAT-3 (serine 727) and induce cell death
We have previously shown that EGCG, a receptor tyrosine kinase inhibitor, can inactivate VEGF-R1 and VEGF-R2 in CLL B cells (based on reduced levels of phosphorylation). 26 In the current work, we have found that activated VEGF-R1 and VEGF-R2 physically complex with p-STAT-1 and p-STAT-3 ( Figure 3 ). We therefore examined the impact of EGCG on p-STAT-1 and p-STAT-3 levels in CLL B cells. EGCG decreased levels of serine p-STAT-3 but not serine p-STAT-1 (Figure 6a and b) . This inhibition of serine p-STAT-3 was also found to be associated with the downregulation of the Bcl-2 family member Mcl-1 (Figure 6c ). Other BCL-2 family molecules (Bcl-2; survivin) were not affected by exposure to EGCG (Figure 6c ). Since EGCG has functions other than tyrosine kinase inhibition, 46 we also used a specific receptor tyrosine kinase inhibitor (SU11657) known to inhibit VEGF-R1 and VEGF-R2 activation 47 to validate blocking VEGF receptor phosphorylation decreases phosphorylation of STAT 3 and induces apoptosis in CLL B cells. SU11657 inhibited phosphorylation of VEGF-R1 and VEGF-R2 (Figure 7a and b) , downregulated serine p-STAT-3 (Figure 7c ), and induced apoptosis/cell death in CLL B cells (Figure 7d ). The SU11657 dose required to inhibit phosphorylation of VEGF receptors was similar to the dose that induced CLL B-cell death (12.5 mM). Similar to results with EGCG, culture of CLL B cells with SU11657 also led to downregulation of Mcl-1 at the 12.5 mM dose (data not shown). These results suggest that EGCG and SU11657 mediate apoptosis of CLL B cells through mechanisms that involve inhibition of the VEGF receptor signaling pathway.
Neutralization of VEGF decreases levels of p-STAT-3 and induces cell death
To further validate the role of VEGF receptors in STAT protein activation and CLL B-cell apoptotic resistance, we investigated the effect of two commercially available VEGF neutralizing antibodies (Bevaczumab and R and D MAB 293) on levels of p-STAT-3 in whole-cell lysate, nuclear extracts and cell viability (Bevaczumab). At lower doses, VEGF neutralizing antibodies decreased VEGF-R1 and VEGF-R2 phosphorylation (Figure 8a ) as well as decreased levels of p-STAT-3 (Figure 8a and b) without a significant impact on cell viability. Importantly, we have found that these antibodies decrease the levels of activated VEGF-R2 and STAT 3 in both nuclear extract and whole-cell lysates (Figure 8a and b) . The decrease in activated receptor and STAT proteins appears to be greater in nuclear extract than whole-cell lysate, which is suggesting that inhibition of VEGF-R2 activation disrupts both activation and nuclear translocation of STAT 3. Figure 8c , however, does show that a VEGF neutralizing antibody can induce CLL B-cell apoptosis/cell death in a dose-dependent manner. This latter finding further adds to the data that VEGF can protect CLL B cells from apoptosis.
Discussion
This study shows that CLL B cells abundantly overexpress serine p-STAT-1 and p-STAT-3 relative to normal B cells by both immunofluorescence and immunoprecipitation analysis. In addition, serine p-STAT-1 and p-STAT-3 proteins are physically associated with VEGF-R1 and VEGF-R2. We have published that VEGF-R1 and VEGF-R2 are spontaneously phosphorylated, 26 and our current experiments strongly suggest that of STAT 1 and/ or STAT 3 complex with activated (ie, tyrosine phosphorylated) VEGF receptors. These latter findings indicate that there is significant biologic relevance to this complex of STAT proteins and VEGF receptors. Addition of recombinant VEGF to these CLL B cells induced selective nuclear translocation of STAT 3 STAT 3 colocalizes with both VEGF-R1 and VEGF-R2 at the perinuclear region upon VEGF stimulation. Isolated CLL cells were treated with VEGF 165 (100 ng/ml) for 45 min at 41C to recruit ligand-bound receptor at the cell surface, and then warmed up to 371C for the time indicated to enable endocytosis. Cells were counterstained for both p-STAT-3 and VEGF receptors (for VEGF-R1 (see a, b) and for VEGF-R2 (see c, d)) with specific antibodies. All images were collected using the LSM 510 program on a Zeiss microscope at a magnitude of Â 63. Data shown above are representative of three different patients (N ¼ 3). Note that VEGF receptors (red fluorescence) and STAT 3 (green fluorescence) were initially localized on cell membrane and cytoplasm, respectively; upon VEGF stimulation, both VEGF receptors and STAT 3 formed complexes (note yellow color) and were now located at the perinuclear membrane pointed out in this figure by the arrows.
but not STAT 1, and similar experiments with PLGF suggest that this translocation requires VEGF-R2. Importantly, inhibition of VEGF receptor phosphorylation with two different tyrosine kinase inhibitors (EGCG and SU11657) or with VEGF neutralizing antibodies was associated with downregulation of VEGF receptor phosphorylation, decreased p-STAT-3, decreased Mcl-1, and induction of apoptosis/CLL B-cell death.
These findings have important implications for VEGF receptor signaling, apoptotic resistance, and enhanced survival in CLL B cells. It has been previously reported that constitutive STAT 1 and STAT 3 phosphorylation is present in CLL B cells but is limited to the serine 727 site with minimal tyrosine p-STAT-1 and p-STAT-3. 37 We have confirmed these observations by immunofluorescence or immunoprecipitation (Table 1 , Figures  1 and 2) . Whether phosphorylation of STAT 1 and STAT 3 at the tyrosine site is required for transcription or phosphorylated at serine 727 alone is sufficient for efficient transcription remains an important question. It is notable, however, that serine 727 phosphorylation of STAT 3 is necessary for maximal STAT protein-induced transcription 48 and, the inability of STAT 3 to be phosphorylated at the serine site can result in embryonic lethal effects in mice. 40 Several studies have found the serine sites on STAT 1 and STAT 3 are essential for cytokine-stimulated transcription activation based on mutation analysis. 41, [49] [50] [51] [52] Previous studies have demonstrated that p-STAT-3 may be able to interact with other factor(s) to initial transcription activation without phosphorylation on the tyrosine sites. 39, 44, 45 Previously, we have shown that CLL B cells spontaneously secrete VEGF 4 and express constitutively phosphorylated VEGF-R1 and VEGF-R2. 26 Importantly, these receptors contain phosphorylated tyrosine sites on their SH 2 domain 5, 53 suggesting the possibility of an autocrine VEGF pathway in CLL B cells. 26 Based on studies demonstrating constitutive activation of STAT 1 and STAT 3 in CLL B cells, [35] [36] [37] we wondered if constitutively activated VEGFR in CLL B cells might recruit STAT molecules to generate survival signals. In the current work, we used a sequential immunoprecipitation followed by immunoblotting strategy to determine if VEGF-R and STAT molecules were physically associated in CLL B cells. We found that both VEGF-R1 and VEGF-R2 are complexed with p-STAT-1 and p-STAT-3 ( Figure 3) . We have also shown that recombinant VEGF can increase VEGF-R phosphorylation, 26 increase STAT phosphorylation (Figure 4a) , and induce perinuclear translocation of EGCG selectively inhibits p-STAT-3 levels and leads to downregulation of Mcl-1 and XIAP in CLL B cells. Freshly isolated CLL B cells were cultured in serum-free AIM-V medium with or without EGCG (3.12-25 mg/ml) for 24 h. Protein extract (500 mg) was prepared and then subjected to SDS-PAGE, and transferred to nitrocellulose. Blot was probed with (a) serine p-STAT-1 and (b) serine p-STAT-3 antibody. b-Actin from the whole-cell lysate was used to detect equal loading. To examine the impact of EGCG on antiapoptotic molecules, cell lysate (50 mg) used for the data in (a) and (b) was also used for the immunoblot assessing the Mcl-1, XIAP, Bcl-2 and survivin levels (see 6c). Data shown above are representative of three different experiments from three different patients. A549 cell line whole-cell lysate was used as a positive control. STAT 3 (Figure 4c ). This result suggests that CLL B cells utilize VEGF to activate STAT molecules via VEGF receptors.
The cellular location of p-STAT-1 and p-STAT-3 molecules in CLL B cells is another unique aspect of this study. We were able to detect serine p-STAT-3 in both the cytoplasm and nucleus of CLL B cells, whereas serine p-STAT-1 was predominantly found in the cytoplasm. Importantly, when exposed to exogenous VEGF, CLL B cells had selective nuclear translocation of p-STAT-3 but not p-STAT-1 (Figures 4a, b and 5 ). These observations were confirmed by nuclear extraction assays used to enrich for nuclear protein from CLL B cells (Figure 4c ). Since tyrosine phosphorylation of STAT proteins is typically required for translocation of STAT 3 to the nucleus, 42 how nontyrosine p-STAT-3 translocates to the nucleus in CLL B cells is unclear. Other reports have suggested that receptor-mediated endocytosis may facilitate nuclear STAT transport. 39, 44, 45 Our finding that STAT 3 physically complexes with VEGF receptors and exogenous VEGF induces nuclear translocation of both VEGF-R and STAT 3 raises the possibility of VEGF receptor-mediated endocytosis facilitating the delivery of p-STAT-3 to the nucleus of CLL B cells. Other recent reports of STAT 3 nuclear translocation by receptor-mediated endocytosis 45 and a VEGFbased autocrine pathway is associated with VEGF-R2 nuclear translocation in acute myeloid leukemia cells 54 further support this possibility.
Our finding that the VEGF-VEGF-R pathway in CLL B cells utilizes STAT molecules for signaling is in contrast to VEGF signaling in endothelial cells. In these cells, the predominant signaling pathway downstream of the VEGF and VEGF-R interaction have most commonly been linked to the mitogenactivated protein kinase cascade. 27 To evaluate potential crosstalk between other signaling pathways that have been implicated in STAT activation (MAPK, JAK, Src, and PI3 K), we used commercially available inhibitors of these pathways to determine if they facilitated STAT activation in CLL B cells (see Materials and methods). Blocking these pathways had little or no impact on either levels of activated STAT 3 or CLL B-cell viability by FACS analysis (data not shown) suggesting VEGFinduced activation of STAT molecules in CLL B cells is likely independent of the JAK-Src, PI3 K, and ERK signaling pathways. We have also previously demonstrated the absence of AKT and ERK molecules in CLL B cells making it even less likely these molecules play a critical role in STAT activation in CLL B cells. Although the relationship of STAT proteins to VEGF function has not been fully clarified, endothelial cells exposed to VEGF have been shown to activate STAT protein 28 and VEGF added to bovine endothelial cells results in STAT 1 and STAT 6 tyrosine phosphorylation and nuclear translocation. 55 In these experiments with endothelial cells, VEGF exposure induced STAT 3 tyrosine phosphorylation but no nuclear translocation of STAT 3 protein.
Serine phosphorylation of STAT 3 has been shown to be essential for Mcl-1 expression in human monocytes 43 and Mcl-1 is an important molecule in CLL B-cell apoptotic resistance. 56 We previously reported that VEGF could induce an increase in specific antiapoptotic proteins (Mcl-1 and XIAP) in CLL B cells. 26 The addition of EGCG, the main component of green tea, was found to inhibit phosphorylation of VEGF receptors, VEGF-induced increases of Mcl-1 and XIAP, and increase levels of apoptosis in CLL B cells. 26 In the current study, we did not find p-STAT-3 in the cytoplasm or nucleus of normal B cells from spleen or tonsil tissue but found abundant nuclear p-STAT-3 in CLL B cells. Based on the finding STAT molecules physically complex with VEGF receptors, we explored the effect of inhibiting VEGF receptor activation on the STAT phosphorylation status in CLL B cells. We found that inhibition of VEGF receptor activation by tyrosine kinase inhibitors (EGCG and SU11657) selectively downregulated the p-STAT-3 level (Figure 6b ) and also resulted in the downregulation of Mcl-1 (Figure 6c ). These results confirm the role of the VEGF-VEGF-R pathway in regulation of antiapoptotic proteins in CLL B cells and support our hypothesis that STAT molecules mediate effects of VEGF receptor signaling. Finally, to substantiate the presence of a VEGF autocrine pathway in CLL B cells and confirm interruption of VEGF receptor stimulation leads to decreased STAT 3 activation and induction of apoptosis, we evaluated the effect of VEGF neutralizing antibodies on CLL B cells. These experiments demonstrate that neutralization of VEGF leads to inhibition of VEGF receptor activation, decreased p-STAT-3, decreased Mcl-1, and increased cell death. When considered with previously published findings, 4, 5, 26, 53, 54 these results substantiate the existence of a VEGF autocrine pathway in CLL B cells, the importance of VEGF receptor signaling in CLL B cell survival, 26 and the potential role of STAT 3 in VEGF receptor signaling. 28, [35] [36] [37] 43 In this work, we have confirmed the presence of constitutive serine p-STAT-1 and p-STAT 3 in CLL B cells and demonstrated p-STAT-1 and p-STAT-3 physically complex with VEGF receptors. We have also shown stimulation of CLL B cells with VEGF induces nuclear translocation of p-STAT-3. Using both tyrosine kinase inhibitors (EGCG and SU11657) and VEGF neutralizing antibodies (bevaczumab and R&D monoclonal antibody 293) to inhibit activation of VEGF-R1 and VEGF-R2, we found consistent decreases in VEGF receptor phosphorylation and activation of STAT 3 as well as induction of apoptosis in CLL B cells. Collectively, these findings highlight the importance of the VEGF pathway and the potential role of STAT 3 in VEGF receptor signaling to enhance CLL B cells survival. 28, [35] [36] [37] 43 
